A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS
单位：[1]Peking Union Medical College Hospital, Beijing, China[2]The First Affiliated Hospital of BaoTou Medical College, Inner Mongolia University of Science and Technology, Baotou, China内蒙古科技大学包头医学院[3]The First Hospital of Jilin University, Changchun, China[4]Peking University First Hospital, Beijing, China[5]The First Affiliated Hospital of Xi’an Jiaotong University, Xi’an, China[6]Guandong Provincial People’s Hospital, Guangzhou, China[7]China-Japan Friendship Hospital, Beijing, China[8]The First Hospital of Shanxi Medical University, Taiyuan, China[9]The First Affiliated Hospital of Kunming Medical University, Kunming, China昆明医科大学附属第一医院[10]Beijing Hospital, Beijing, China[11]Peking University Third Hospital, Beijing, China[12]Xiangya Hospital Central South University, Changsha, China[13]Shanghai Henlius Biotech Inc., Shanghai, China[14]Beijing Tian Tan hospital, Capital Medical University, Beijing, China首都医科大学附属天坛医院
第一作者单位：[1]Peking Union Medical College Hospital, Beijing, China
推荐引用方式(GB/T 7714)：
Zeng Xiaofeng,Wang Yongfu,Jiang Zhenyu,et al.A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS[J].ANNALS of the RHEUMATIC DISEASES.2019,78:1140-1140.doi:10.1136/annrheumdis-2019-eular.3669.
APA：
Zeng, Xiaofeng,Wang, Yongfu,Jiang, Zhenyu,Zhang, Zhuoli,He, Lan...&Chen, Xia.(2019).A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS.ANNALS of the RHEUMATIC DISEASES,78,
MLA：
Zeng, Xiaofeng,et al."A MULTICENTRE, RANDOMISED, DOUBLE-BLIND, PARALLEL ACTIVE-CONTROLLED CLINICAL TRIAL COMPARING PHARMACOKINETICS, PHARMACODYNAMICS, SAFETY AND EXPLORATORY EFFICACY BETWEEN HLX01 AND EUROPE-SOURCED RITUXIMAB AS A NEW INDICATION IN CHINESE MODERATE TO SEVERE PATIENTS WITH RHEUMATOID ARTHRITIS".ANNALS of the RHEUMATIC DISEASES 78.(2019):1140-1140
医学